The Laboratory of Veterinary Internal Medicine II, School of Veterinary Medicine, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonan Cho, Musashino-shi, 180-8602 Tokyo, Japan.
The Laboratory of Veterinary Internal Medicine II, School of Veterinary Medicine, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, 1-7-1 Kyonan Cho, Musashino-shi, 180-8602 Tokyo, Japan.
Res Vet Sci. 2020 Dec;133:150-156. doi: 10.1016/j.rvsc.2020.09.019. Epub 2020 Sep 22.
Renal proteinuria is associated with promoted renal dysfunction and a shorter survival period in dogs with chronic kidney disease (CKD). Renin angiotensin- aldosterone system inhibitors are primarily used to treat renal proteinuria. In this retrospective, open-label study, we aimed to evaluate the anti-proteinuric and anti-hypertensive effects of telmisartan (angiotensin II receptor blocker) in dogs with proteinuric CKD. A total of 28 dogs with proteinuric CKD were included in the study, all dogs received telmisartan 1 mg/kg q24h, PO. The urine protein-to-creatinine ratio (UPC), urine albumin-to-creatinine ratio (UAC) and systolic blood pressure (SBP) decreased significantly after telmisartan administration (P < 0.05). The median rate of change in UPC, UAC and SBP at Day 120 were - 65.1%, -75.9% and - 9.7%. Ten dogs (36.7%) achieved UPC < 1.0 at Day 120, of which six dogs had UPC < 0.5. A reduction of UPC to ≥50% was achieved in 10 dogs (36%) at Day 45 and 17 dogs (61%) at Day 120. Seventeen dogs (61%) had hypertension at baseline, of which 10 dogs (59%) had SBP < 160 mmHg at Day 120. Two-way repeated measures analysis of variance did not attribute the observed changes in SBP, UPC or UAC to feeding with a renal diet. In conclusion, telmisartan therapy provides anti-proteinuric and anti-hypertensive effects in dogs with proteinuric CKD.
肾性蛋白尿与犬慢性肾病（CKD）的肾功能恶化和生存时间缩短有关。肾素-血管紧张素-醛固酮系统抑制剂主要用于治疗肾性蛋白尿。在这项回顾性、开放性研究中，我们旨在评估替米沙坦（血管紧张素 II 受体阻滞剂）在患有蛋白尿性 CKD 的犬中的抗蛋白尿和降压作用。共有 28 只患有蛋白尿性 CKD 的犬纳入本研究，所有犬均接受替米沙坦 1mg/kg q24h，PO 治疗。替米沙坦给药后，尿蛋白/肌酐比值（UPC）、尿白蛋白/肌酐比值（UAC）和收缩压（SBP）均显著降低（P<0.05）。第 120 天时 UPC、UAC 和 SBP 的中位数变化率分别为-65.1%、-75.9%和-9.7%。第 120 天时，有 10 只犬（36.7%）的 UPC<1.0，其中 6 只犬的 UPC<0.5。第 45 天有 10 只犬（36%）和第 120 天有 17 只犬（61%）达到 UPC 降低≥50%。在基线时有 17 只犬（61%）患有高血压，其中 10 只犬（59%）在第 120 天时 SBP<160mmHg。双向重复测量方差分析未将 SBP、UPC 或 UAC 的观察到的变化归因于食用肾脏饮食。结论：替米沙坦治疗可在患有蛋白尿性 CKD 的犬中提供抗蛋白尿和降压作用。
